Long-term efficacy and safety of anti-hyperglycaemic agents in new-onset diabetes after transplant: Results from outpatient-based 1-year follow-up and a brief review of treatment options
- 23 November 2020
- journal article
- review article
- Published by Elsevier BV in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 15 (1), 13-19
- https://doi.org/10.1016/j.dsx.2020.11.019
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world settingIndian Journal of Endocrinology and Metabolism, 2013
- Early Basal Insulin Therapy Decreases New-Onset Diabetes after Renal TransplantationJournal of the American Society of Nephrology, 2012
- Should Metformin Be Our Antiglycemic Agent of Choice Post-transplantation?American Journal of Transplantation, 2011
- Kidney transplant in diabetic patients: modalities, indications and resultsDiabetology & Metabolic Syndrome, 2009
- Hyperglycemia during the Immediate Period after Kidney TransplantationClinical Journal of the American Society of Nephrology, 2009
- Influence of Lifestyle Modification in Renal Transplant Recipients With Postprandial HyperglycemiaTransplantation, 2008
- Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activityAmerican Journal of Physiology-Endocrinology and Metabolism, 2005
- Pioglitazone in the Management of Diabetes Mellitus after TransplantationAmerican Journal of Transplantation, 2004
- NEW-ONSET DIABETES AFTER TRANSPLANTATION: 2003 INTERNATIONAL CONSENSUS GUIDELINES1Transplantation, 2003
- ??-CELL DYSFUNCTION RATHER THAN INSULIN RESISTANCE IS THE MAIN CONTRIBUTING FACTOR FOR THE DEVELOPMENT OF POSTRENAL TRANSPLANTATION DIABETES MELLITUSTransplantation, 2001